parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	group enriched, including oligodendrocytes; strongest in retinal pigment epithelial cells	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 5921

receipt 5930: ERMN in dopamine neurons, braak

power: full sample +0.26 (p 0.294, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.25 (p 0.310, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.35 (p 0.150, n 18). could be the mix.
skeptic: leave-one-out range +0.19 to +0.46, sign flips 0; without severely affected donors +0.26 (p 0.294, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ERMN in dopamine neurons.

case closed: nothing better to follow up.

receipt 5929: ERMN in oligodendrocytes, braak

power: full sample +0.06 (p 0.814, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.671, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.09 (p 0.715, n 18). could be the mix.
skeptic: leave-one-out range -0.06 to +0.19, sign flips 4; without severely affected donors +0.06 (p 0.814, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ERMN in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts